Business
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the successful completion of process tech transfer and product introduction to Thermo Fisher Scientific, the world leader in serving science, for IBTROZI® (taletrectinib) to treat advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The transition was submitted as a supplement to the IBTROZI New Drug Application held by Nuv
About this update from Nuvation Bio Inc.
[{"type":"text","content":"Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United States","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"Move by Nuvation Bio further ensures critical drug supply for patients and providers","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, May 13, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the successful completion of process tech transfer and product introduction to Thermo Fisher Scientific, the world leader in serving science, for IBTROZI® (taletrectinib) to treat advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The transition was submitted as a supplement to the IBTROZI New Drug Application held by Nuvation Bio and is now complete.","length":569,"tagName":"p"},{"type":"image","alt":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio Inc.)","displaySize":"","headline":null,"caption":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":67,"url":"https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/orXZwjggSXGuOiVNNE1jOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988","width":400,"height":67},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/JmdGUzs_3BFkeDVasf.b6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEwNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988","width":400,"height":67}},"href":"https://mma.prnewswire.com/media/2924210/Nuvation_Bio_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Our commitment to unencumbered access to IBTROZI for appropriate patients with ROS1+ NSCLC starts at the manufacturing stage, where we work to ensure that our collaborators and processes deliver critical medicine with high quality," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "We are pleased to collaborate with Thermo Fisher, a leading contract manufacturer of pharmaceuticals, to bring IBTROZI manufacturing closer to the ...